Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Amprion, Inc. is a company headquartered in San Francisco, CA. The firm develops early detection testing devices. It was founded in 2006 by Russ M. Lebovitz and Claudio Soto. Russ M. Lebovitz is currently the CEO of the company.\nThe company says this about itself: A leader in prion detection science, Amprion innovates biomarker testing. The company offers its first commercial diagnostic application, SYNTap? Biomarker Test, to aid physicians in the clinical diagnosis of Parkinson's Disease (PD) and Lewy Body Dementia (LBD). This breakthrough test identifies misfolded Synuclein aggregates, a hallmark in various neurodegenerative diseases. The innovative assay can also be used to distinguish underlying synucleinopathy in patient evaluation for other neurological disorders, such as Alzheimer's Disease (AD).

G.D. Searle, LLC is a wholly owned trademark of Pfizer. It is currently used mainly as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Prior to its 1985 merger with Monsanto, Searle was a company focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

InFlectis BioScience is leveraging its leading expertise in the cellular defense system against misfolded proteins and drug discovery to identify and develop small molecules which modulate key proteins involved in misfolded protein disorders. Endoplasmic Reticulum (ER) proteostasis is vital for cellular function and cell survival. Many different perturbations can alter the folding capacity of the ER and may cause accumulation of unfolded or misfolded proteins inside the ER, a cellular condition referred to as ER stress. To safeguard proteostasis, the mammalian ER has a complex machinery to maintain the integrity of cells. This adaptive programme is called the unfolded protein response (UPR).

Develops and manufactures drugs related to immunology, neurobiology and oncology

Based in China and led by U.S. diagnostic industry veterans, Shuwen Biotech is engaged in licensing and developing innovative diagnostic products and services for disease prevention, diagnosis and personalized medicine, and strives to offer in China a comprehensive menu of the most innovative diagnostic products and services for improved disease prediction, screening, diagnosis, prognosis and treatment.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Domantis Ltd. develops antibody molecules. Domantis Ltd. offers dual targeting human domain antibodies, which are used against cytokine targets for inflammatory diseases, tumour antigens present on the same tumour cells, and tumour growth/angiogenic factors for solid tumours; human domain antibodies with tailored serum half-life that are customized to achieve the desired therapeutic effect; human domain antibodies for diverse therapeutic targets, which are suited to inhibit receptor targets; and injectable and non-injectable human domain antibodies that treat diseases of the lung, as well as disorders of the gastro-intestinal tract.

GestVision, Inc. is commercializing a point of care diagnostic test for preeclampsia. The pregnancy-related condition is often characterized by the symptoms of high blood pressure and protein in the urine. Left untreated, the condition can lead to seizures and even death. Preeclampsia is an equal opportunity problem and is of concern in both developed and developing nations. The US is not immune and sees preeclampsia as a growing problem.

Celtrix is a biopharmaceutical company focused on developing novel therapeutics for the treatment of seriously debilitating, degenerative conditions primarily associated with severe trauma, chronic diseases or aging.

UK Research & Innovation (doing business as United Kingdom Research & Innovation) is a private company headquartered in London, UK. The firm provides science and technology research services.\nThe company says this about itself: Innovate UK is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government. We drive productivity and economic growth by supporting businesses to develop and realise the potential of new ideas, including those from the UK’s world-class research base.

Research Development Foundation is an American private company that operates as noncommercial research organizations.

Expedeon is an expert in cutting-edge innovative reagents and services for life sciences and diagnostics, with application across workflows including: protein electrophoresis; liquid biopsy; whole genome amplification; antibody- and protein-labeling; and immunoassay development. Our cutting-edge offerings include off-the-shelf products, and custom services, supporting scientists from academia through to commercial manufacturing across the life sciences and diagnostic industry. Expedeon’s dedicated team of experts has the flexibility to develop and supply consistently high quality products both off-the-shelf and to customer specification. We are constantly innovating to provide high quality, easy-to-use, cost-effective solutions, to minimize hands-on time for researchers. All our products are stringently QC tested, and are designed to save scientists time and costs. Expedeon is wholly owned by SYGNIS AG and has laboratory facilities and commercial sites in the UK, USA, Singapore, Germany and Spain. Expedeon provides fast, global delivery. Off-the-shelf products are available with next-day delivery and quick turnaround times are offered on custom product generation.

Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ.